Fig. 6

Discriminative prognosis power of the identified subpathway signatures. Left: Forest plot shows HR and 95% CI from univariate Cox proportional hazards model of the subpathway signatures at three omic level from LGG-temozolomide and PAAD-gemcitabine. Right: Kaplan–Meier survival plots of patients grouped by K-means based on combined activities with multi-omics of subpathway signatures in LGG and PAAD. The P values were estimated based on log rank test